ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025
[Research Progress on Interleukin-6 in Screening and Prognosis of Patients with Non-small Cell Lung Cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC), the predominant histological subtype of lung cancer, mandates precise screening and accurate prognostic assessment to guide therapeutic strategies and improve patient survival. The initiation and progression of NSCLC are intimately linked to inflammatory responses. Interleukin-6 (IL-6), a pivotal inflammatory mediator, critically modulates the tumor microenvironment, immune evasion, tumor progression, and therapy resistance in NSCLC. Recent evidence indicates that IL-6 not only participates in the biological behavior of NSCLC but also holds promise as a potential biomarker for early detection and prognostication. This review summarizes the role of IL-6 in NSCLC screening, treatment-related adverse events, and its utility in the management of NSCLC-associated comorbidities. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.